Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Assets (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Assets for 16 consecutive years, with $742.9 million as the latest value for Q1 2026.

  • Quarterly Assets fell 0.71% to $742.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $742.9 million through Jan 2026, down 0.71% year-over-year, with the annual reading at $742.9 million for FY2026, 0.71% down from the prior year.
  • Assets for Q1 2026 was $742.9 million at Usana Health Sciences, up from $726.6 million in the prior quarter.
  • The five-year high for Assets was $748.2 million in Q4 2024, with the low at $556.1 million in Q4 2022.
  • Average Assets over 5 years is $643.2 million, with a median of $629.3 million recorded in 2024.
  • The sharpest move saw Assets decreased 9.85% in 2022, then increased 18.64% in 2025.
  • Over 5 years, Assets stood at $596.5 million in 2022, then rose by 6.07% to $632.8 million in 2023, then increased by 18.24% to $748.2 million in 2024, then decreased by 2.89% to $726.6 million in 2025, then grew by 2.25% to $742.9 million in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $742.9 million, $726.6 million, and $734.5 million for Q1 2026, Q3 2025, and Q2 2025 respectively.